There is no shortage of firms seeking to become a pan-European licensing partner of choice. They want the growing number of products from smaller firms, particularly Americans, who are—theoretically--seeking a European partner capable of accessing all European markets, and likely to provide the focus and commitment that Big Pharma might not.
Few have achieved that goal. Domestic firms like Almirall Prodesfarma or Chiesi Farmaceutici SPA claim to be expanding across...




